Eastern Cooperative Oncology Group
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2012-01-01
- Employees
- 51
- Market Cap
- -
- Website
- https://ecog-acrin.org
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
Phase 3
Not yet recruiting
- Conditions
- Interventions
- Other: Best PracticeProcedure: Autologous Hematopoietic Stem Cell TransplantationProcedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: Positron Emission TomographyDrug: High Dose ChemotherapyProcedure: LeukapheresisDrug: Stem Cell Mobilization Therapy
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 294
- Registration Number
- NCT06724237
Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial Treatment
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-11-28
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 184
- Registration Number
- NCT05628623
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-03-21
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 20
- Registration Number
- NCT05289687
- Locations
- 🇺🇸
Northwestern, Chicago, Illinois, United States
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-11-04
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 400
- Registration Number
- NCT05108298
- Locations
- 🇺🇸
Grant Medical Center, Columbus, Ohio, United States
🇺🇸Flaget Memorial Hospital, Bardstown, Kentucky, United States
🇺🇸Saint Joseph London, London, Kentucky, United States
COVID-19 Related Financial Hardship and Distress in Women Who Decline TMIST (EA1151) Participation
- First Posted Date
- 2021-10-13
- Last Posted Date
- 2023-06-23
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 14
- Registration Number
- NCT05076266
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
Phase III rhu_GM-CSF + 3 Induction Regimens in Adults With Acute Non-Lymphocytic Leukemia
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 362
- Registration Number
- NCT04446052
Double Blind Phase III Trial of Effects of Low Dose 13-Cisretinoic Acid on Prevention of Second Primaries in Stages I-II Head and Neck Cancer
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-12-12
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 189
- Registration Number
- NCT03370367
C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer
Phase 1
Withdrawn
- Conditions
- Stage IIIA Esophageal CancerStage IIIA Gastric CancerStage IIIB Esophageal CancerStage IIIB Gastric CancerAdenocarcinoma of the EsophagusIntestinal Adenocarcinoma of the StomachAdenocarcinoma of the Gastroesophageal JunctionMixed Adenocarcinoma of the StomachStage IIIC Esophageal CancerStage IIIC Gastric Cancer
- Interventions
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2023-05-25
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Registration Number
- NCT02344810
- Locations
- 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States
A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
Not Applicable
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2013-04-05
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 1046
- Registration Number
- NCT01824836
- Locations
- 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
🇺🇸Veterans Adminstration New Jersey Health Care System, East Orange, New Jersey, United States
PSA Antibody Levels in Samples From Patients With Prostate Cancer Treated on Protocol ECOG-E9802
Completed
- Conditions
- First Posted Date
- 2012-08-27
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 20
- Registration Number
- NCT01672905
© Copyright 2024. All Rights Reserved by MedPath